Cagrilintide API and Research Peptide Supplier

What is Cagrilintide?

Cagrilintide is a long-acting amylin analogue: a 37-amino-acid acylated peptide that acts as an agonist at amylin (AMY) and calcitonin (CTR) receptors. It is built on a pramlintide-like amylin backbone with sequence substitutions and N-terminal acylation by a C20 eicosanedioic fatty di-acid attached through a γGlu linker, plus an intramolecular disulfide bridge. The acylation drives albumin binding and confers a long elimination half-life.

As a chemical substance, cagrilintide (CAS 1415456-99-3, molecular formula C194H312N54O59S2, ~4409 g/mol) is typically handled as a lyophilised powder. It is being studied for obesity and weight management, including as part of a fixed combination with a GLP-1 receptor agonist. Cagrilintide is investigational: it is in clinical development and has not been approved by the FDA, EMA or other major regulators.

How Cagrilintide Is Produced & Characterised

Cagrilintide is a synthetically demanding acylated peptide: the 37-mer length, the disulfide bridge requiring controlled oxidative folding, and the lipid side-chain conjugation all create opportunities for deletion sequences, diastereomers, mis-folded variants and incomplete acylation. For this peptide class, production is generally based on Fmoc solid-phase peptide synthesis (SPPS) with controlled disulfide formation and side-chain conjugation, followed by purification on preparative dynamic axial compression (DAC) HPLC columns that isolates the target sequence from closely related impurities, and lyophilisation to a stable powder.

Quality control for acylated amylin analogues of this type typically combines UPLC/HPLC for purity, LC-MS for confirmation of sequence and disulfide connectivity, and characterisation of water content, counter-ion (acetate) content and residual solvents. These analytical approaches reflect general industry practice for complex peptides.

Regulatory & Development Context

Cagrilintide is an investigational molecule: it is in clinical development for obesity and weight management and has not been approved by the FDA, EMA or other major regulators. It has been studied both as a standalone amylin analogue and in fixed combination with a GLP-1 receptor agonist.

For investigational peptides such as cagrilintide, chemistry, manufacturing and controls (CMC) information is generally organised under CTD Module 3 to support IND/CTA submissions, with analytical methods validated to ICH Q2(R1) and stability assessed to ICH Q1A(R2). This section summarises the general regulatory framework that applies to molecules of this type and reflects cagrilintide's current investigational status.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Cagrilintide to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Cagrilintide in their country.